HOME >> MEDICINE >> NEWS
Common PTSD drug is no more effective than placebo

women or older versus younger veterans. In addition, the subjects who took guanfacine had significantly more somnolence, lightheadedness, and dry mouth than those who took placebo.

The study authors conclude, These results do not support the use of alpha 2 agonists in veterans with chronic PTSD.

Neylan speculates that instead of lowering the overall level of norepinephrine, a more effective approach might be to inhibit the ability of brain cells to respond to the neurotransmitter. He notes that this is the action of prazosin, a blood pressure medication that has been found by other researchers to decrease the incidence of nightmares in combat veterans with PTSD.


'"/>

Contact: Steve Tokar
steve.tokar@ncire.org
415-221-4810 x5202
University of California - San Francisco
1-Dec-2006


Page: 1 2

Related medicine news :

1. Commonly used drug offers promise for premature babies
2. Commonly used pain medications do not prevent Alzheimers disease
3. Common anesthetic may induce cell death, generation of Alzheimers-associated protein
4. Common blood pressure drug treats muscular dystrophy in mice
5. Common cold may be just a fingertip away due to environmental contamination
6. Commonwealth Fund commission says the US health care system needs thorough transformation
7. Commonly recommended sedative does not improve infant sleep
8. Common asthma inhaler causing deaths, researchers assert
9. Common painkillers associated with increased risk of first hospital admission for heart failure
10. Commonly used blood pressure medication prevents aortic aneurysm in mice with Marfan syndrome
11. Common osteoporosis treatment may help men with prostate cancer suffering from bone loss

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Common PTSD drug more effective than placebo

(Date:7/31/2014)... Women over the age of 65 face numerous barriers ... struggles against poverty and higher rates of asthma with ... issue of Annals of Allergy, Asthma and Immunology ... Allergy, Asthma and Immunology (ACAAI), outlines the challenges faced ... solutions to improve their care. , "Allergists ...
(Date:7/31/2014)... 2014 The 2013 PolyU TSI ... points from 75.07 in 2012. The index measures ... and integrates them into an overall index. The ... more satisfied with Hong Kong over time. , ... in service performance in Hong Kong are attractions ...
(Date:7/31/2014)... 2014 Ce-Classes.com has announced that they ... healthcare professionals, a Systematic Review of Sexual Satisfaction ... in the International Journal of Clinical and Health Psychology. ... to a need to have accurate information about sexual ... treatment possible. The material provides a systematic review ...
(Date:7/31/2014)... GA (PRWEB) July 31, 2014 In today’s ... increasingly difficult to get. Snoring and sleep apnea (a medical ... rob people and their bed partners of the rest they ... 45% of the population snores and 20 million people in ... 10% have been diagnosed and treated; and of those treated, ...
(Date:7/31/2014)... Weblify has finally been released by marketing and advertising ... The result is a perfected and fine tuned platform ... minutes without knowing any HTML or other programming languages. , ... SEO expert, agrees that this platform allows anyone to create ... web site builders out there, but this is truly unique. ...
Breaking Medicine News(10 mins):Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3
(Date:7/31/2014)... , July 31, 2014 Catylix, Inc. ... Scientific ( Milpitas, California ) announced ... develop and commercialize new fluorination products and related ... has benefited from the use of substituents that ... lipophilicity with polarity to improve binding and bioavailability. ...
(Date:7/31/2014)... the list of stocks featured in the Analyst Blog. Every ... and events impacting stocks and the financial markets. Stocks recently ... Free Report ), Gilead (Nasdaq: GILD - Free Report ... AbbVie (NYSE: ABBV - Free Report ) and Celgene ... Zacks is promoting its ,Buy, stock recommendations. Get #1Stock ...
(Date:7/31/2014)... Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company ... conference call on Thursday, August 14, 2014, at 4:30 p.m. ... June 30, 2014. Financial results will be issued in a ... President and CEO James LaFrance will host the ... Date: Thursday, August 14, 2014 Time: 4:30 p.m. Eastern time ...
Breaking Medicine Technology:Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
Cached News: